Bruker (NASDAQ:BRKR) Stock Price Up 6.9% – Time to Buy?

Bruker Corporation (NASDAQ:BRKR) rose 6.9% on Wednesday . The company traded as high as $61.10 and last traded at $61.2830. Approximately 1,753,429 shares changed hands during trading, a decline of 27% from the average daily volume of 2,395,581 shares. The stock had previously closed at $57.31.

Analysts Set New Price Targets

BRKR has been the subject of a number of research analyst reports. UBS Group lifted their target price on shares of Bruker from $40.00 to $45.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Weiss Ratings lowered shares of Bruker from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday. Barclays upped their price target on shares of Bruker from $45.00 to $53.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Finally, TD Cowen increased their price target on Bruker from $43.00 to $45.00 and gave the company a “hold” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $50.54.

Bruker Trading Up 7.3%

The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. The company has a market cap of $9.36 billion, a P/E ratio of -254.96, a PEG ratio of 3.50 and a beta of 1.31. The firm’s 50 day moving average is $40.64 and its two-hundred day moving average is $42.98.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter in the previous year, the firm posted $0.47 earnings per share. Bruker’s revenue for the quarter was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts anticipate that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be given a $0.05 dividend. The ex-dividend date is Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s payout ratio is presently -83.33%.

Insider Activity

In other Bruker news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 27.20% of the company’s stock.

Hedge Funds Weigh In On Bruker

Hedge funds have recently modified their holdings of the company. Los Angeles Capital Management LLC purchased a new position in shares of Bruker in the fourth quarter valued at about $26,000. Allworth Financial LP boosted its stake in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares in the last quarter. Essential Partners LLC bought a new stake in shares of Bruker during the 1st quarter valued at about $36,000. Parallel Advisors LLC boosted its stake in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares in the last quarter. Finally, Summit Securities Group LLC bought a new stake in shares of Bruker during the 4th quarter valued at about $50,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.